Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

Articles

Evolving HCC Treatment Landscape: Combination Therapy

October 30th 2020

Developing Trial Regimens for Chinese Populations

October 30th 2020

High AFP as Deciding Factor for Treatment

October 30th 2020

Immunotherapy Monotherapy in Later-Line Setting

October 30th 2020

Second-Line Options After IMbrave150 Regimen

October 30th 2020

Promising Ongoing Frontline Trials

October 30th 2020

Importance of Endoscopy in Newly Diagnosed HCC

October 30th 2020

NCCN Guidelines: Nivolumab in Frontline Setting

October 30th 2020

Choosing a Frontline Therapy

October 30th 2020

Optimal HCC Frontline Treatments

October 30th 2020

The TACE Approach for Intermediate-Stage Disease

October 30th 2020

The BCLC Staging System

October 30th 2020

Screening Vs Diagnosis: Assessing Liver Function

October 30th 2020

The Complexity of HCC Multidisciplinary Management

October 30th 2020

HCC: Applying Recent Data Into Practice

July 13th 2020

HCC: Emerging Therapies Under Investigation

July 13th 2020

Combination Regimens for HCC Treatment

July 13th 2020

Emerging Biomarkers in Hepatocellular Carcinoma

July 13th 2020

HCC: Liver Function and Treatment Decisions

July 13th 2020

Safety Profiles of Novel Therapies for HCC

July 13th 2020